Avantax Advisory Services, Inc. Crispr Therapeutics Ag Transaction History
Avantax Advisory Services, Inc.
- $16 Billion
- Q1 2025
A detailed history of Avantax Advisory Services, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 10,651 shares of CRSP stock, worth $679,001. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,651
Previous 6,836
55.81%
Holding current value
$679,001
Previous $269,000
34.57%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
63.9MCall Options Held
2.16MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$648 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$387 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$242 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$177 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.54MShares$162 Million0.06% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.97B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....